177Lu-DOTA-JR11

an somatostatin receptor antagonist

Also Known As:

177Lu-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-Cpa-cyclo(d-Cys-amino-Phe-hydroorotic acid-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)-D-Tyr-NH2; 177Lu-DOTA-(Cpa-c(DCys-Aph(Hor)-DAph(Cbm)-Lys-Thr-Cys)-DTyr-NH2); 177Lu-OPS201

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Cyclic Peptides: 530
    - 177Lu-DOTA-JR11: 4
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Cyclic Peptides: 530
    - 177Lu-DOTA-JR11: 4
Inorganic Chemicals: 9
- Coordination Complexes: 576
  - 177Lu-DOTA-JR11: 4
Organic Chemicals: 133
- Coordination Complexes: 576
  - 177Lu-DOTA-JR11: 4

Experts

1.	Fani, Melpomeni: 2 articles (01/2019 - 01/2017)
2.	Kaufmann, Jens: 2 articles (01/2019 - 01/2017)
3.	Wild, Damian: 2 articles (01/2019 - 01/2017)
4.	Albrecht, Jakob: 1 article (01/2021)
5.	Beindorff, Nicola: 1 article (01/2021)
6.	Brenner, Winfried: 1 article (01/2021)
7.	Exner, Samantha: 1 article (01/2021)
8.	Grötzinger, Carsten: 1 article (01/2021)
9.	Konietschke, Frank: 1 article (01/2021)
10.	Koziolek, Eva J: 1 article (01/2021)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 10/01/2017 - "One patient-derived xenograft, the estrogen receptor-positive model T126, was chosen to generate in vivo mouse models containing orthotopic breast tumors for in vivo SPECT/MRI and biodistribution studies after injection with 177Lu-DOTA-Tyr3-octreotate or 177Lu-DOTA-JR11. "
2.	Neoplasms (Cancer) 01/01/2021 - "Imaging of tumor morphology indicated comparatively larger necrotic fractions for 177Lu-DOTA-JR11 despite further tumor growth. " 01/01/2021 - "We evaluated PRRT with SSTR agonist 177Lu-DOTATOC and antagonist 177Lu-DOTA-JR11 longitudinally in an orthotopic murine pancreatic neuroendocrine neoplasm model expressing human SSTR2. " 01/01/2021 - "Multimodal Imaging of 2-Cycle PRRT with 177Lu-DOTA-JR11 and 177Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model." 01/01/2017 - "Importantly, and in contrast to 177Lu-DOTATATE, injection of 10, 200, and 2,000 pmol of 177Lu-OPS201 did not cause any relevant tumor saturation, with tumor uptake 4 h after injection: 23.9, 24.9, and 18.8 percentage of injected activity per gram of tissue (%IA/g), respectively, for the antagonist (P > 0.05), as compared with 17.8, 12.0, and 9.9 %IA/g for the agonist (P < 0.05). " 01/01/2017 - "The overall tumor-to-kidney dose ratio was approximately 24% and 32% higher for 177Lu-OPS201 than for 90Y-OPS201 and 177Lu-DOTATATE, respectively. "
3.	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/01/2019 - "177Lu-OPS201 is a high-affinity somatostatin receptor subtype 2 antagonist for PRRT in patients with neuroendocrine tumors. "

Related Drugs and Biologics

1.	Estrogen Receptors
2.	Somatostatin Receptors (Somatostatin Receptor)
3.	DOTA(0)-Tyr(3)- 177Lu-octreotide
4.	lutetium Lu 177 dotatate

Related Therapies and Procedures

1.	Therapeutics
2.	Intravenous Injections